🇺🇸 FDA
Patent

US 12000829

Selection of patients for combination therapy

granted A61KA61K2039/54A61K2039/545

Quick answer

US patent 12000829 (Selection of patients for combination therapy) held by Syndax Pharmaceuticals, Inc. expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Syndax Pharmaceuticals, Inc.
Grant date
Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/54, A61K2039/545, A61K31/4406, A61K39/3955